Eisai wraps filing for Biogen-partnered Aduhelm follow-up, hoping to regain ‘credibility and trust’news2022-05-09T19:54:53+00:00May 9th, 2022|FierceBiotech|
More Moma: $150M series B will push precision cancer drugs to clinic by 2024news2022-05-09T19:13:33+00:00May 9th, 2022|FierceBiotech|
Sesen Bio reports progress with regulators as it preps for new cancer trial, but issues remainnews2022-05-09T15:01:32+00:00May 9th, 2022|FierceBiotech|
Investors take root in Aspen Neuroscience’s customized cell therapy as $147.5M round closesnews2022-05-09T14:45:08+00:00May 9th, 2022|FierceBiotech|
LogicBio’s sun and shares rise again after FDA releases clinical hold on pediatric genome editing therapynews2022-05-09T14:11:29+00:00May 9th, 2022|FierceBiotech|
J&J axes Bavarian Nordic pact for HPV and Hep B vax, keeps two other programsnews2022-05-09T13:53:25+00:00May 9th, 2022|FierceBiotech|
J&J axes Bavarian Nordic pact for HPV and hep B vax, keeps 2 other programsnews2022-05-09T13:53:25+00:00May 9th, 2022|FierceBiotech|
Investors flip-flop on Nykode’s cancer vaccine data dropnews2022-05-09T10:36:18+00:00May 9th, 2022|FierceBiotech|
Another Oxurion eye disease drug flunks phase 2, leaving biotech all-in on last prospectnews2022-05-09T09:31:11+00:00May 9th, 2022|FierceBiotech|
UPDATE: VistaGen says regulators couldn’t sniff out abuse potential of its nasal spray for social anxietynews2022-05-06T14:32:28+00:00May 6th, 2022|FierceBiotech|
